.png)
.png)
Arecor to present at the Sixth China Healthcare Summit 2019 in Shanghai, China
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its Chief Executive Officer, Dr Sarah Howell, will present at The sixth China Healthcare Summit, held from 18th to 20th November at the Jing An Shangri-La, Shanghai, China.
The Sixth China Healthcare Summit is the leading international forum to discuss how China is building the bridge to global healthcare. Dr Sarah Howell will address how UK Biopharmaceutical companies such as Arecor can collaborate with the growing innovative Chinese biotech ecosystem and investment community. Her presentation will focus on Arecor’s Arestat™ technology platform’s ability to develop superior biopharmaceuticals through the innovative reformulation of proteins and peptides, enabling the advancement of current treatments for diabetes and other conditions.
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Mo PR Advisory www.mopradvisory.com
Mo Noonan Mob: +44 (0) 7876 444977
Email: [email protected]
About Arecor
Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
Arestat™ is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of approved therapeutic proteins and peptides. Arecor’s proprietary products leverage Arestat™ to enable improved treatments for diabetes including an ultra-rapid acting insulin for Type I diabetes and an ultra-concentrated (up to 100U/mL) rapid acting insulin, as well as a portfolio of undisclosed pre-clinical candidates. Our clinical programmes are significantly de-risked because we reformulate existing approved products with known safety and efficacy profiles.
For our partners, we use Arestat™ to deliver superior reformulations of their proprietary products, which would otherwise not be possible.
The Sixth China Healthcare Summit is the leading international forum to discuss how China is building the bridge to global healthcare. Dr Sarah Howell will address how UK Biopharmaceutical companies such as Arecor can collaborate with the growing innovative Chinese biotech ecosystem and investment community. Her presentation will focus on Arecor’s Arestat™ technology platform’s ability to develop superior biopharmaceuticals through the innovative reformulation of proteins and peptides, enabling the advancement of current treatments for diabetes and other conditions.
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Mo PR Advisory www.mopradvisory.com
Mo Noonan Mob: +44 (0) 7876 444977
Email: [email protected]
About Arecor
Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
Arestat™ is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of approved therapeutic proteins and peptides. Arecor’s proprietary products leverage Arestat™ to enable improved treatments for diabetes including an ultra-rapid acting insulin for Type I diabetes and an ultra-concentrated (up to 100U/mL) rapid acting insulin, as well as a portfolio of undisclosed pre-clinical candidates. Our clinical programmes are significantly de-risked because we reformulate existing approved products with known safety and efficacy profiles.
For our partners, we use Arestat™ to deliver superior reformulations of their proprietary products, which would otherwise not be possible.